SCHEMBL21671871

SCHEMBL21671871

CN1CCN(C)c2ccc([N+](=O)[O-])cc2C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 1/20 0.50
LMNA P02545 5/20 0.49
ALDH1A1 P00352 8/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C19 P33261 2/20 0.48
HTT P42858 2/20 0.48
GAA P10253 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
WDR5 P61964 3/20 0.45
POLB P06746 1/20 0.45
SIRT2 Q8IXJ6 1/20 0.45
KDM4E B2RXH2 1/20 0.44
HTR7 P34969 1/20 0.43
CASP1 P29466 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3885369 0.83 SIRT2 (0.55) SIRT6LMNAALDH1A1CYP1A2CYP3A4
SCHEMBL9499652 0.80 L3MBTL1 (0.51) SIRT6LMNAALDH1A1CYP1A2CYP3A4
SCHEMBL3481133 0.80 ALDH1A1 (0.55) SIRT6LMNAALDH1A1CYP1A2CYP3A4
SCHEMBL29558059 0.80 ADRA2A (0.51) SIRT6LMNAALDH1A1HTTSMN1; SMN2
SCHEMBL324724 0.80 ADRA2A (0.51) SIRT6LMNAALDH1A1HTTSMN1; SMN2
SCHEMBL2061992 0.79 ALDH1A1 (0.51) LMNAALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL29990004 0.78 MAOA (0.50) SIRT6LMNAALDH1A1HTTSMN1; SMN2
Hydrochloric Acid SCHEMBL7832321 0.78 ADRA2A (0.50) SIRT6LMNAALDH1A1HTTSMN1; SMN2
SCHEMBL20232216 0.78 MAOA (0.50) SIRT6LMNAALDH1A1HTTSMN1; SMN2
SCHEMBL29945643 0.77 DPP7 (0.50) SIRT6LMNAALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11248006-B2 Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2022-02-15 US disclosed
EP-3604306-A1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai de Novo Pharmatech Co., Ltd. (CN) 2020-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11248006-B2 Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof WEE1, WEE2, PDPK1 SIRT6 1967/4885LMNA 4334/4885ALDH1A1 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.